Low Number of Donor Activating Killer Immunoglobulin-Like Receptors (KIR) Genes but not KIR-Ligand Mismatch Prevents Relapse and Improves Disease-Free Survival in Leukemia Patients After In Vivo T-Cell Depleted Unrelated Stem Cell Transplantation
- 27 October 2006
- journal article
- research article
- Published by Wolters Kluwer Health in Transplantation
- Vol. 82 (8) , 1024-1030
- https://doi.org/10.1097/01.tp.0000235859.24513.43
Abstract
Background. The effect of natural killer (NK) cell alloreactivity on outcome of unrelated stem cell transplantation (SCT) remains controversial. Killer immunoglobulin-like receptors (KIRs) recognize human leukocyte antigen C and B epitopes on target cells, thereby regulating NK cell activity. The KIR genes are polymorphic and two broad haplotypes exist: KIR-haplotype A mainly encode for inhibitory receptors and only for one activating (KIR2DS4), whereas the group B haplotype encodes more for activating KIRs (KIR2DS1, KIR2DS2, KIR2DS3, KIR2DS5 und KIR3DS1). Methods. The impact of KIR ligand mismatch on the number of activating and inhibitory donor KIR genes and on KIR-haplotype was studied on outcome of 142 patients with leukemia, who received standard myeloablative conditioning followed by in vivo T-cell depleted (ATG) unrelated SCT. Results. In a multivariate analysis KIR ligand mismatch had significantly higher treatment related mortality (RR 2.206, P=0.03), resulting in reduced overall (RR 2.015, P=0.02) and disease-free survival (RR 1.924, P=0.03). In contrast, SCT from donors with group A haplotype (P=0.003) or with low number of activating KIR genes (P=0.005) resulted in reduced relapse rate with improved disease-fee survival (P=0.04). This effect was seen only in acute myeloid leukemia/myelodysplastic syndrome and to a less extent in chronic myeloid leukemia. No effect was seen for acute lymphoblastic leukemia. Conclusions. After in vivo T-cell depleted (ATG) unrelated stem cell transplantation with donors carrying low number of activating KIR genes (group A KIR haplotype), the risk of relapse is reduced and resulted in a significantly better disease-free survival.Keywords
This publication has 18 references indexed in Scilit:
- Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypesBlood, 2005
- Comparison of Killer Ig-Like Receptor Genotyping and Phenotyping for Selection of Allogeneic Blood Stem Cell DonorsThe Journal of Immunology, 2005
- Genotypic inhibitory killer immunoglobulin-like receptor ligand incompatibility enhances the long-term antileukemic effect of unmodified allogeneic hematopoietic stem cell transplantation in patients with myeloid leukemiasBlood, 2005
- Increased Infection-Related Mortality in KIR-Ligand–Mismatched Unrelated Allogeneic Hematopoietic Stem-Cell TransplantationTransplantation, 2004
- Role of KIR ligand incompatibility in hematopoietic stem cell transplantation using unrelated donorsBlood, 2004
- The beneficial role of inhibitory KIR genes of HLA class I NK epitopes in haploidentically mismatched stem cell allografts may be masked by residual donor‐alloreactive T cells causing GVHDTissue Antigens, 2004
- Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donorsBlood, 2003
- Evaluation of KIR ligand incompatibility in mismatched unrelated donor hematopoietic transplantsBlood, 2002
- Relevance of KIR gene polymorphisms in bone marrow transplantation outcomeHuman Immunology, 2002
- Effectiveness of Donor Natural Killer Cell Alloreactivity in Mismatched Hematopoietic TransplantsScience, 2002